Large cell neuroendocrine carcinoma (LCNEC) of the ovary: A case report and review of the literature

Jang, Allyson; Newell, Jordan M.; Phaëton, Rébécca; Kesterson, Joshua

doi:10.15761/icst.1000217

Cited by 3 publications

(3 citation statements)

References 10 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, SCCOHT is usually diagnosed in younger women and is extremely aggressive, with a median OS between 5 and 14.5 months [110]. The ovarian LCNEC is the rarest variant among ovarian NENs (less than 10 cases have been reported in the literature so far) and is characterized by a highly aggressive behavior and a median survival of 10 months from diagnosis [111][112][113]. Given the rarity of these tumors, available data mainly derive from case reports and small case series, and thus, there are no dedicated recommendations or guidelines [77].…”

Section: Necs Of the Ovarymentioning

confidence: 99%

Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives

Stumpo,

Formelli,

Persano

et al. 2023

JCM

View full text Add to dashboard Cite

Neuroendocrine carcinomas (NECs) are poorly differentiated and highly aggressive epithelial neuroendocrine neoplasms. The most common primary site is the lung, but they may arise in every organ. Approximately 37% of extrapulmonary NECs (EP-NECs) occur in the gastroenteropancreatic (GEP) tract, followed by the genitourinary (GU) system and gynecological tract. As a result of their rarity, there is scant evidence to guide treatment recommendations, and a multidisciplinary approach is essential for the management of such patients. Platinum-based chemotherapy currently represents the standard of care for EP-NECs of any site, mirroring the management of small-cell lung cancer (SCLC), but further approaches are still under investigation. Indeed, ongoing trials evaluating targeted therapies, immune checkpoint inhibitors (ICIs), and radionuclide therapy could provide potentially breakthrough therapeutic options. Given the relative dearth of evidence-based literature on these orphan diseases, the aim of this review is to provide an overview of the pathology and current treatment options, as well as to shed light on the most pressing unmet needs in the field.

show abstract

Section: Necs Of the Ovarymentioning

confidence: 99%

Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives

Stumpo,

Formelli,

Persano

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Small cell carcinomas of the ovary do not have a clearly established therapy, but most cases are treated through surgical excision followed by chemotherapy (cisplatin and etopiside) [25]. Large cell neuroendocrine carcinomas usually have a similar therapy with six cycles of cisplatin (90 mg/m 2 ) and etoposide or paclitaxel (175 mg/m 2 ), although some articles have reported recurrences after 10 months [88]. If lymph node metastases are observed, then the patient can also undergo multiple sessions with 75 mg/m 2 Taxotere every three weeks [88].…”

Section: Neuroendocrine Neoplasms Of the Ovarymentioning

confidence: 99%

“…Large cell neuroendocrine carcinomas usually have a similar therapy with six cycles of cisplatin (90 mg/m 2 ) and etoposide or paclitaxel (175 mg/m 2 ), although some articles have reported recurrences after 10 months [88]. If lymph node metastases are observed, then the patient can also undergo multiple sessions with 75 mg/m 2 Taxotere every three weeks [88].…”

Section: Neuroendocrine Neoplasms Of the Ovarymentioning

confidence: 99%

Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract

et al. 2021

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NENs) are particularly rare in all sites of the gynecological tract and include a variety of neoplasms with variable prognosis, dependent on histologic subtype and site of origin. Following the expert consensus proposal of the International Agency for Research on Cancer (IARC), the approach in the latest World Health Organization (WHO) Classification System of the Female Genital Tumours is to use the same terminology for NENs at all body sites. The main concept of this novel classification framework is to align it to all other body sites and make a clear distinction between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). The previous WHO Classification System of the Female Genital Tumours featured more or less the same principle, but used the terms ‘low-grade neuroendocrine tumor’ and ‘high-grade neuroendocrine carcinoma’. Regardless of the terminology used, each of these two main categories include two distinct morphological subtypes: NETs are represented by typical and atypical carcinoid and NEC are represented by small cell neuroendocrine carcinoma (SCNEC) and large cell neuroendocrine carcinoma (LCNEC). High-grade NECs, especially small cell neuroendocrine carcinoma tends to be more frequent in the uterine cervix, followed by the endometrium, while low-grade NETs usually occur in the ovary. NENs of the vulva, vagina and fallopian tube are exceptionally rare, with scattered case reports in the scientific literature.

show abstract

The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions

Caruso

Sassu

Tomao

et al. 2021

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Large cell neuroendocrine carcinoma (LCNEC) of the ovary: A case report and review of the literature

Cited by 3 publications

References 10 publications

Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives

Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives

Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract

The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions

Contact Info

Product

Resources

About